Nuclear Medicine.
Clinical Oncology Departments, Kasr Al-Ainy Hospital, Cairo University, Egypt.
Nucl Med Commun. 2021 Feb 1;42(2):216-224. doi: 10.1097/MNM.0000000000001316.
To assess the role of 18F-FDG PET/CT in initial staging of head and neck squamous cell carcinoma and its impact on changing the management compared to other conventional methods.
A prospective study of 31 patients (21 male and 10 female), mean age 49.3 ± 12.1 years with histologically confirmed squamous cell carcinoma of the head and neck (nasopharynx was the commonest cancer in 15 patients (48.4%), poorly differentiated grade represented 64.5% of all tumors. Initial staging was achieved according to routine physical examination, endoscopy, CT, U/S, MRI.
The overall change in TNM staging by 18F-FDG PET/CT in relation to conventional methods was encountered in 15/31 patients (48.4%). PET/CT changed; T staging in three patients (9.6%), upstaging in two patients and downstaging in one patient. PET/CT upstaged all 13/31 patients in N staging (41.9%). 18F-FDG PET/CT changed; M staging in 3/31 (9.6%) patients, upstaging in two and downstaging in one patient. PET/CT results caused radiotherapy modification in 21/31 patients (67.7%). PET/CT detected intra-parotid nodule in four patients, so additional radiation was added to the parotid in the treatment field. Retropharyngeal nodes were detected by PET/CT in three patients that were missed by conventional imaging. 18F-FDG PET/CT detected two patients of thyroid papillary carcinoma and one case of sigmoid neoplasm confirmed by histopathology.
18F-FDG-PET/CT is considered a valuable diagnostic test in head and neck squamous cell carcinoma at initial assessment which would change staging and radiotherapy planning and hence proper management.
评估 18F-FDG PET/CT 在头颈部鳞状细胞癌初始分期中的作用及其与其他常规方法相比改变治疗管理的作用。
对 31 例(21 例男性和 10 例女性)经组织学证实的头颈部鳞状细胞癌患者进行前瞻性研究,平均年龄为 49.3±12.1 岁。鼻咽是 15 例患者(48.4%)中最常见的癌症,所有肿瘤中分化程度差者占 64.5%。初始分期根据常规体格检查、内窥镜检查、CT、超声、MRI 进行。
18F-FDG PET/CT 与常规方法相比,31 例患者中有 15 例(48.4%)的 TNM 分期发生总体变化。PET/CT 改变了 3 例患者(9.6%)的 T 分期,2 例患者分期升高,1 例患者分期降低。PET/CT 使 13 例患者(41.9%)的 N 分期升高。18F-FDG PET/CT 改变了 3 例患者(9.6%)的 M 分期,2 例患者分期升高,1 例患者分期降低。PET/CT 结果使 21 例患者(67.7%)的放疗方式发生改变。PET/CT 在 4 例患者中检测到腮腺内结节,因此在治疗野中增加了对腮腺的放射。PET/CT 在 3 例患者中检测到常规影像学遗漏的咽后淋巴结。18F-FDG PET/CT 检测到 2 例甲状腺乳头状癌和 1 例乙状结肠肿瘤患者,这些患者均经组织病理学证实。
18F-FDG-PET/CT 被认为是头颈部鳞状细胞癌初始评估的一种有价值的诊断检测方法,它可以改变分期和放疗计划,从而进行适当的治疗管理。